Salta al contenuto principale
Passa alla visualizzazione normale.

GIUSEPPE SALEMI

The pharmacological management of myelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD): an update of the literature

  • Autori: Schirò, Giuseppe; Iacono, Salvatore; Salemi, Giuseppe; Ragonese, Paolo
  • Anno di pubblicazione: 2024
  • Tipologia: Review essay (rassegna critica)
  • Parole Chiave: MOGAD; interleukin-6; optic neuromyelitis spectrum disorders; rituximab; satralizumab; tocilizumab
  • OA Link: http://hdl.handle.net/10447/650053

Abstract

IntroductionMyelin oligodendrocyte glycoprotein-immunoglobulin G associated disease (MOGAD) is a clinical entity distinct from multiple sclerosis and aquaporin-4 (AQP4+)-IgG-positive neuromyelitis optica spectrum disorder. There is a lack of evidence regarding the efficacy and safety of current treatments used for MOGAD.Areas coveredIn this article, the authors review the currently available literature on the pharmacological management of MOGAD. This article is based on an extensive search for articles including meta-analyses, clinical trials, systematic reviews, observational studies, case series and case reports.Expert opinionIntravenous high-dose methylprednisolone is the most common therapy for acute attack with patients having a good treatment response. In cases with poor recovery, intravenous immunoglobulins (IVIG) or plasma-exchange proved to be effective. Maintenance therapies include mycophenolate mofetil, azathioprine, IVIG, oral corticosteroids, rituximab, and interleukin-6 receptor (IL6-R) antagonists. Rituximab is the most used drug while IL6-R antagonists emerged as an effective option for people not responding to current treatments. Larger prospective studies with longer follow-ups are needed to confirm whether the blockage of the IL6-R is an effective and safe option. Since there is no evidence of major safety issues related to the new available therapies, the authors believe that waiting for disease activity to consider a possible treatment change, is an unwise approach.